about
New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progressionOne is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason gradingIdentification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer.What is the molecular pathology of low-risk prostate cancer?Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs).Human papillomavirus DNA in glandular lesions of the uterine cervix.Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers.Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point.International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling.Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens.Recently described and unusual variants of urothelial carcinoma of the urinary bladder.Premalignant lesions of the urinary bladder.Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations.Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem?Percutaneous renal tumour biopsy.Mesenchymal tumors of adult kidney.Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.Mucin expression by transitional cell carcinomas of the bladder.Gleason and Fuhrman no longer make the grade.The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer.A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma.Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways.Prostate cancer grading: recent developments and future directions.Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features.Evidence for steroidogenic potential in human prostate cell lines and tissues.Gleason grading: past, present and future.Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells.Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot-assisted laparoscopic prostatectomies.Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration.Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression.A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP.Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study.Intravascular fasciitis: a case report and review of the literature.Atypical presentation of herpes simplex (chronic hypertrophic herpes) in a patient with HIV infection.Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases.An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer.Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management.Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation.
P50
Q21143810-E78BA5D3-C83A-4FFA-8A20-9BBB68118940Q28070143-A202BCBA-3C86-458D-A4E5-AE953CC3F3DEQ36858042-B66B502C-495F-43CB-ACCD-477848DD9680Q37137644-03AC29A4-D34D-408F-A13C-BBC9618F3F98Q37216570-497A397D-B6AB-4B1F-B74B-1D408C4EF65DQ37238982-22FECB64-AB33-435C-892B-E349BD07876FQ37273884-91BD0ADC-F789-4796-BA38-59D5BFB39497Q37741236-78B87352-7E0D-4CBD-BA31-7DFD03E38857Q37787737-D56492F4-1EAE-43BA-AC7D-95A6F71D264FQ37895892-FD30E26B-2F26-4522-8CA6-832090F94868Q38024963-010F51FE-462C-413C-BECF-0DFEBA871F71Q38085435-4CA53E56-344E-45D3-8299-A820C4C10ACEQ38136414-7E3D3A9A-6000-469E-AC80-7928B0084700Q38156337-1170A3D8-517D-4740-AD26-71B4B5365981Q38231652-2E3164C4-6AAC-4CD9-B123-B2F615757F0AQ38378932-7C77BF52-E98F-4D5B-9514-C6C0318D04D4Q38426753-79B0B972-C937-4ABF-B36E-6B5093123AD8Q38483920-8C5C2950-0026-4583-A462-9E1547A551C1Q38565256-8680A055-7829-4F86-BD09-549963C910A7Q38577959-1B8E06A7-D680-4D88-B974-D3B860F09584Q38763962-8462BFC5-308D-43B4-A8D7-E987D9B43831Q38784843-A883AECD-3963-41E4-882B-73E5E2AC5FB6Q38812333-2D187A45-E757-4F94-9CFC-92AE2E83966BQ38870444-E863EA32-805C-4E8D-B416-CECC1ED822E8Q39314632-338351E1-80F1-4107-8AA7-71627BDF5D26Q39668527-5974ECAE-A9EB-4454-B48E-E9B16CEC8F33Q39735812-D0158E83-1724-4EB8-966E-7E2EF616B81DQ39859117-F21F86F2-BC75-4B33-9022-F8030BCD03C4Q39931278-F609CA4E-2879-428A-8C3D-875CAF933AACQ40007756-D826F432-4C58-465A-98B1-23F8488A4C5FQ40024991-3353B63F-90F9-4C62-88A8-F389F673D557Q40344892-732F8D7D-5B2F-454D-91EA-71B2D0B97F6CQ40597484-DA698C3D-2E46-4B93-8F68-CC4F8100B3BAQ40969858-03A3B05E-4B6A-43A3-951F-0494BDDB8A85Q41037545-DA280C87-AC11-4AE4-BE66-4272B852B1BCQ43876579-A1537CF6-B647-4014-B727-1E495791C522Q44271939-14FEF27E-85F6-4042-8427-6A5FE90B3123Q44465832-0B52F743-FBDA-44F9-BD2D-A0760038B4DAQ44845472-F9386AE9-37D3-4681-8B87-6404299441B5Q45106063-6BD0709C-B175-466E-AFDD-B94E15B75118
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hemamali Samaratunga
@ast
Hemamali Samaratunga
@en
Hemamali Samaratunga
@es
Hemamali Samaratunga
@nl
Hemamali Samaratunga
@sl
type
label
Hemamali Samaratunga
@ast
Hemamali Samaratunga
@en
Hemamali Samaratunga
@es
Hemamali Samaratunga
@nl
Hemamali Samaratunga
@sl
prefLabel
Hemamali Samaratunga
@ast
Hemamali Samaratunga
@en
Hemamali Samaratunga
@es
Hemamali Samaratunga
@nl
Hemamali Samaratunga
@sl
P1053
D-1559-2013
P106
P1153
6701312565
P31
P3829
P496
0000-0001-5796-1791